Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Goodman

Showing results (771-780 of 1,119) with videos related to

Pageof 112
Sort By:
The American Journal of Cardiology|September 11, 2007
Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100 mg/dl versus<100 mg/dlFrederick A Spencer, Robert J Goldberg, Joel M Gore, et al.
Diabetes Care|March 16, 2021
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab TreatmentGregory G Schwartz, Michael Szarek, Vera A Bittner, et al.
American Heart Journal|April 1, 2009
Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromesRajeev V Rao, Shaun G Goodman, Raymond T Yan, et al.
The Canadian Journal of Cardiology|August 31, 2011
Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromesAhmed Krimly, Raymond T Yan, Andrew T Yan, et al.
JAMA Cardiology|December 9, 2020
Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical TrialDerek P Chew, Karice Hyun, Erin Morton, et al.
Critical Pathways in Cardiology|February 21, 2024
Current Gaps in the Provision of Safe and Effective Anticoagulation in Atrial Fibrillation and the Potential for Factor XI-Directed TherapeuticsShaun G Goodman, Denis Roy, Charles V Pollack, et al.
The Canadian Journal of Cardiology|April 3, 2019
Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS TrialPadma Kaul, Karen P Alexander, E Magnus Ohman, et al.
International Journal of Clinical Practice|January 15, 2021
Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) ProgrammeKori Leblanc, Alan D Bell, Justin A Ezekowitz, et al.
JAMA|May 13, 2010
Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005Harindra C Wijeysundera, Márcio Machado, Farah Farahati, et al.
Journal of the American College of Cardiology|September 15, 2000
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary EventsS G Goodman, M Cohen, F Bigonzi, et al.
Pageof 112

Showing results (771-780 of 1,119) with videos related to

Sort By:
Pageof 112
The American Journal of Cardiology|September 11, 2007
Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100 mg/dl versus<100 mg/dlFrederick A Spencer, Robert J Goldberg, Joel M Gore, et al.
Diabetes Care|March 16, 2021
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab TreatmentGregory G Schwartz, Michael Szarek, Vera A Bittner, et al.
American Heart Journal|April 1, 2009
Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromesRajeev V Rao, Shaun G Goodman, Raymond T Yan, et al.
The Canadian Journal of Cardiology|August 31, 2011
Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromesAhmed Krimly, Raymond T Yan, Andrew T Yan, et al.
JAMA Cardiology|December 9, 2020
Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical TrialDerek P Chew, Karice Hyun, Erin Morton, et al.
Critical Pathways in Cardiology|February 21, 2024
Current Gaps in the Provision of Safe and Effective Anticoagulation in Atrial Fibrillation and the Potential for Factor XI-Directed TherapeuticsShaun G Goodman, Denis Roy, Charles V Pollack, et al.
The Canadian Journal of Cardiology|April 3, 2019
Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS TrialPadma Kaul, Karen P Alexander, E Magnus Ohman, et al.
International Journal of Clinical Practice|January 15, 2021
Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) ProgrammeKori Leblanc, Alan D Bell, Justin A Ezekowitz, et al.
JAMA|May 13, 2010
Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005Harindra C Wijeysundera, Márcio Machado, Farah Farahati, et al.
Journal of the American College of Cardiology|September 15, 2000
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary EventsS G Goodman, M Cohen, F Bigonzi, et al.
Pageof 112